Vir Biotechnology's VIR-5818 Shows Promise in Cancer Treatment with Phase 1 Data
- Vir Biotechnology's Phase 1 data show promising results for T-cell engagers VIR-5818 and VIR-5500 in cancer treatment.
- Early results indicate 50% tumor shrinkage in participants with HER2-positive tumors using VIR-5818, showcasing effective treatment potential.
- Vir's innovative PRO-XTEN™ technology aims to enhance T-cell engager efficacy while reducing collateral damage to healthy cells.
Vir Biotechnology Reveals Promising Phase 1 Data for Novel T-Cell Engagers in Cancer Treatment
Vir Biotechnology, Inc. has recently unveiled initial Phase 1 data for its innovative dual-masked T-cell engagers (TCEs), VIR-5818 and VIR-5500, targeting distinct cancer types. VIR-5818 is designed for HER2-expressing solid tumors, while VIR-5500 focuses on metastatic castration-resistant prostate cancer (mCRPC). The preliminary results are encouraging, showcasing not only a favorable safety profile but also early signs of efficacy. Notably, the trials report no incidents of cytokine release syndrome (CRS) or the maximum tolerated dose (MTD) being reached during the ongoing dose escalation phase, which is particularly significant given the high levels of prior treatment experienced by participants.
The early clinical responses observed in heavily pretreated participants underline the potential of Vir’s proprietary PRO-XTEN™ masking technology. This approach aims to selectively activate TCEs within the tumor microenvironment, thereby reducing collateral damage to healthy cells often seen with conventional therapies. CEO Marianne De Backer highlights the critical need to overcome the toxicity limitations prevalent in traditional T-cell engagers, emphasizing that these advancements could fulfill significant medical needs in cancer care. In the trial for VIR-5818, which involves 79 participants receiving the treatment both alone and in combination with pembrolizumab, promising outcomes are already emerging.
Among the findings, early efficacy results indicate that 50% of participants receiving doses of 400 µg/kg or higher experienced tumor shrinkage across various HER2-positive tumors, even among those with extensive prior therapies. Specifically, 33% of participants with HER2-positive colorectal cancer achieved confirmed partial responses, with one patient maintaining a response for over 18 months. These initial results provide strong clinical support for the unique capabilities of PRO-XTEN™ and position VIR-5818 as a potential first-in-class HER2 immunotherapy, addressing a critical gap in effective treatments for solid tumors.
In addition to the promising data for VIR-5818, Vir Biotechnology’s advancements in T-cell engagers reflect a broader trend in immunotherapy, where precision targeting aims to enhance treatment efficacy while minimizing adverse effects. As the company continues its clinical trials, the implications for patients with HER2-expressing cancers could be transformative, paving the way for new standards in oncology care.
Furthermore, the ongoing research into VIR-5500 for mCRPC also underscores Vir’s commitment to addressing significant challenges in cancer treatment. The dual focus on these T-cell engagers reinforces the company’s strategic direction toward harnessing innovative technologies to meet unmet medical needs in oncology.